What Almedis does

Almedis is a Russian Contract Research Organization (CRO) founded in 2006 and headquartered in Moscow. The company provides a full-service portfolio of clinical research capabilities — Medical Writing, Operational Project Management, Data Management, Biostatistics, and Training — to international and local pharmaceutical companies conducting trials in Russia. Across its eighteen-year operating history, Almedis has completed more than 170 projects spanning clinical trial phases I-IV, bioequivalence studies, non-interventional studies, and real-world data studies in therapeutic areas including oncology, infectious diseases, neurology, metabolism, cardiology, endocrinology, surgery, and hepatology. The company maintains a proprietary database of clinical sites with experienced investigators across more than 50 Russian cities, and reports a repeat business rate exceeding 90%.

Almedis's underlying technology stack centers on Ennov Clinical CDMS (used in 70+ projects since 2008 and compliant with CDISC, ICH, and BPC 2001/20/EC standards), SAS for biostatistics (the company was the first SAS subscriber in Russia for clinical trials in 2009), and risk-based monitoring platforms with Key Risk Indicators. Standardized medical coding is enabled through official MedDRA (since 2007) and WhoDrug subscriptions, with the company having participated in the MedDRA Russian translation in 2018-2019. Almedis is an active member of the Association of Clinical Trial Organizations (ACTO) since 2008 and reports working with half of the Top-10 international pharmaceutical companies operating in Russia.

The business model is professional services delivered on a project basis, with flexible combinations of service lines sold directly to pharmaceutical sponsors. Pricing is not publicly disclosed and is tailored to each engagement. The go-to-market relies on direct enterprise relationships, ACTO association membership, industry conference participation, and a corporate website — with no consumer marketing, app, or API surface. The company is privately held with no disclosed institutional investors, funding rounds, or M&A activity in the available source material.

Name

Almedis

Legal name

ALMEDIS

Website

https://almedis.ru

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Almedis is a Moscow-based Contract Research Organization founded in 2006, providing medical writing, project management, data management, biostatistics, and training services to international and local pharmaceutical companies conducting clinical trials in Russia across more than 50 cities.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Medical Writing & Regulatory Submission Support CROs (HLAGAAAG)

Keywords

• Clinical research services
• Contract research organization
• Clinical data management
• Biostatistics services
• Clinical trial management

Headquarters

HQ city

Moscow

HQ country

Russia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Clinical Research Services: Contract research organization providing comprehensive range of clinical research services including Medical Writing, Operational Project Management, Data Management, Biostatistics, and Training. Services are offered as project-based engagements to pharmaceutical companies with flexible combinations of services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Almedis is a Contract Research Organization (CRO) that provides a comprehensive range of clinical research services to pharmaceutical companies in Russia. Its portfolio spans medical writing, operational project management, data management, biostatistics, and training, delivered as project-based engagements supporting international and local clinical trials (phases I-IV), bioequivalence studies, non-interventional studies, and real-world data studies across therapeutic areas including oncology, infectious diseases, neurology, metabolism, cardiology, endocrinology, and hepatology.

Product overview

Almedis is a Contract Research Organization (CRO) providing a comprehensive range of clinical research services in Russia since 2006. The company operates as a single integrated service offering rather than a platform-plus-modules architecture. Its core portfolio consists of five interconnected service lines: Medical Writing Services (protocols, study reports, publications), Operational Project Management Services (feasibility, site selection, monitoring), Data Management Services (eCRF design, database management, medical coding), Biostatistics Services (study design, statistical analysis with SAS), and Training Services (GCP, clinical research topics). These services work together to support international and local clinical trials phases I-IV, bioequivalence studies, non-interventional studies, and real world data studies across various therapeutic areas including oncology, infectious diseases, neurology, and metabolism. The company has performed over 170 projects since inception and maintains its own site database with experienced investigators in over 50 Russian cities.

Differentiator

Problem solved

Functional benefit

Products and services

• Medical Writing Services Comprehensive medical writing for clinical trials and non-interventional studies, including scientific study concept development, protocol writing, patient informed consent form development per ICH GCP requirements, study report writing, pharmacovigilance system documents, product registration dossier preparation per EAEU requirements, and publication preparation for local and international journals. More than 80 medical writing projects completed since 2006.
• Operational Project Management Services Full-package CRO services for the allocation, management, and execution of clinical trials and non-interventional studies, including study feasibility analysis, site selection from a proprietary database of 50+ Russian cities, regulatory submission support, investigator meeting preparation and conduct, project management, risk-based monitoring (mix of centralized and on-site), site management, and clinical trial medication/supplies logistics. More than 50 investigator meetings conducted with 1200+ total participants.
• Data Management Services Full scope of clinical data management services including eCRF/CRF design in Russian or English, database design and testing, data entry and validation, data import from central laboratories, query generation and resolution, medical coding by MedDRA and WhoDrug, SAE reconciliation, and database quality control. Uses Ennov Clinical CDMS (compliant with CDISC, ICH, and BPC 2001/20/EC), successfully used in 70+ projects since 2008.
• Biostatistics Services Statistical services including study design, sample size calculation, randomization (including complex algorithms and stratification), Statistical Analysis Plan development, programming of analysis datasets, tables, listings, and figures, data transfers, and statistical reporting. Uses SAS software (Almedis was the first SAS local subscriber in Russia for clinical trials since 2009), SPSS, and R language, with independent double programming as quality control.
• Training Services Tailored training programs for corporate client staff (Clinical Operations, Medical Affairs, Marketing) and investigators, covering ICH GCP, pediatric clinical trials, statistical aspects of clinical studies, data management processes, PRO and health measurement scales, non-interventional studies, real-world data studies, and investigator-initiated studies. Programs are confirmed by state education certificates via collaboration with the Institute of Laboratory Medicine.

Quantifiable outcome

• 90%+ repeat business rate from existing customers
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core and minor.

• EnnovcoreTechnology or Integration · 1 January 2021Fifteen years of successful collaboration (since 2008) with leading international Life Sciences technology provider Ennov. Almedis uses Ennov Clinical CDMS which complies with international standards (CDISC, ICH, BPC 2001/20/EC) and has been successfully used in more than 70 projects.
• Institute of Laboratory MedicineminorStrategic or Co-development Partner · 1 January 2018In 2018, Almedis launched the Clinical Research Department in collaboration with the Institute of Laboratory Medicine for conducting trainings in clinical research. Successful completion of training programs by investigators is confirmed by a state education certificate.
• SAS InstitutecoreTechnology or Integration · 1 January 2009In Russia, Almedis was the first SAS local subscriber for clinical trials. Using SAS since 2009, Almedis conducts statistical analysis for customers including projects for half of Top-10 international pharmaceutical companies in Russia.
• Association of Clinical Trial Organizations (ACTO)coreOthers · 1 January 2008Almedis has been an active member of ACTO since 2008, participating in the association's work to advance clinical research in Russia. The company works with ACTO on monitoring the clinical trials market and finding optimal solutions to support clinical research.
• MedDRA (Medical Dictionary for Regulatory Activities)coreTechnology or Integration · 1 January 2007Official subscriber of MedDRA since 2007 - an international dictionary of standardized medical terminology used in data management and pharmacovigilance. Almedis participated in MedDRA translation into Russian in 2018-2019.
• Uppsala Monitoring Centre (WHO Drug)coreTechnology or IntegrationAlmedis uses WhoDrug coding in data management and pharmacovigilance operations, accessing international drug terminology standards.

Scale indicators7 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Syneos Health: Biopharmaceutical services organization offering clinical development and commercialization services; directly comparable CRO offering for Almedis' pharmaceutical clients.
• IQVIA: World's largest CRO offering full-service clinical research, data management, biostatistics, and real-world evidence services. Directly comparable full-stack CRO service portfolio to Almedis.
• ICON plc: Global CRO providing Phase I–IV clinical research, biometrics, and consulting — directly overlaps Almedis' medical writing, data management, and biostatistics services.
• PSI CRO: Full-service global CRO with significant Central and Eastern European operations; directly comparable CRO offering targeting similar international pharma clients.
• Parexel: Major global CRO with end-to-end clinical trial services across all phases and therapeutic areas, similar in service breadth to Almedis.
• Worldwide Clinical Trials: Mid-sized global CRO focused on complex Phase II/III trials across neuroscience, oncology, and cardiometabolic — directly comparable to Almedis' therapeutic area mix.
• OCT Clinical: Russian-headquartered CRO offering Phase I–IV clinical trial services, regulatory support, and biometrics. Closest direct domestic competitor to Almedis in the Russian market.
• Pharm-Olam: Mid-sized global CRO with strong presence in Russia/CIS and Eastern Europe offering Phase I–IV services; closely comparable in regional positioning to Almedis.
• ClinStar: Russia-based CRO providing clinical research services to international pharma sponsors across Eastern Europe — directly comparable in geography, service scope, and customer base.

Broad incumbents

• Charles River Laboratories: Large life-sciences services provider with broader preclinical and safety offerings but overlapping clinical/biometrics services relevant to Almedis.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/almedis

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Almedis